Friday, December 27, 2013 1:53:58 AM
You must remember, this lead investigator may sound unphased, but she is speaking with the heart of a mother and the faith of a loving daughter. If she exaggerates her findings, she would not be in her current position at UCLA. She also would be doing a disservice to her brave patients (living and passed).
The key is that L.L. is meticulous about getting to the heart of advances and missteps. She knows the lessons thus far. She has incorporated every nuance into the GBM phase three trial. The worst statistic thus far regarding anything close to her procedure is 90% OS at 1 year, 50+ at 2 years and 47% at 3 years. These are not the percentages we hope for from direct, but if these showed up from the phase 3 DCVAX-L, mankind will take a giant leap.
She stands on the shoulders of giants.... but countless others -- angels and loved ones -- will dance on the head of her scalpel and pen. The Direct trial, while conducted by V.S., will owe pure gratitude to Liau's dedication and ingenuity. I have nothing but admiration for her colleagues and friendly competitors in this field.
As of 2013, 403 patients were included in peer review studies for Dendritic cell therapy on GBM alone! http://www.ncbi.nlm.nih.gov/pubmed/23790634 It is sound science. DCVAX-L has saved birthdays, weddings, births and childhoods. DCVAX-L is not a silver bullet, it is a soldier in a tough ground game. However, it is a prelude to victory for all mankind.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM